Walter Moos has been an adjunct Professor of Pharmaceutical Chemistry at UCSF since 1992. In parallel, he has been a Managing Director of Pandect Bioventures, which he co-founded in 2018. Starting in 2016, first as an advisor, then as CEO, and most recently as Chairman emeritus of ShangPharma Innovation, he led development of the group's innovation ecosystem. He was President of SRI Biosciences until 2016 after more than a decade at the independent nonprofit SRI International (Stanford Research Institute). Moos also managed corporate IT Services at SRI. Earlier he was Chairman/CEO of MitoKor (Migenix) and a VP at Chiron (Novartis) and at Warner-Lambert/Parke-Davis (Pfizer). He and his teams have made significant contributions to all R&D phases from early-stage research on chemical and biological therapeutics and diagnostics to marketed pharmaceutical products. They have done this with the support of VCs, foundations, government agencies, big pharma, and many others. Moos has served on more than 20 business and scientific boards, public and private, non-profit and for-profit, including Alnis, Amunix (Sanofi), Anterion, Aprinoia, Axiom (Sequenom), the Biotechnology Industry Organization (BIO), Circle, the Critical Path Institute, Global Blood, Keystone Symposia, Migenix, Mimotopes (Fisher/Thermo), MitoKor, Oncologic (Aduro/Chinook), Onyx (Amgen), Rigel, ShangPharma Innovation, Valitor, and the Virginia University Research Partnership. He has advised companies on several continents and served as a committee member for academic, government, and investor groups, including the US National Academy of Sciences. He has co-founded several scientific journals, co-authored or edited multiple books, and has nearly 200 patents and publications. Moos has held faculty positions at several major universities and received PhD and AB degrees in chemistry from UC Berkeley and Harvard, respectively.